Towards a scientific blockchain framework for reproducible data analysis by Furlanello, C. et al.
Towards a scientific blockchain framework for
reproducible data analysis
Cesare Furlanello1∗ Manlio De Domenico2† Giuseppe Jurman1 Nicole Bussola1
1 Fondazione Bruno Kessler, Trento, Italy
2 Universitat Rovira i Virgili, Tarragona, Spain
furlan@fbk.eu, manlio.dedomenico@urv.cat, jurman@fbk.eu, bussola@fbk.eu
Abstract
Publishing reproducible analyses is a long-standing and widespread challenge [1]
for the scientific community, funding bodies and publishers [2, 3, 4]. Although a
definitive solution is still elusive [5], the problem is recognized to affect all dis-
ciplines [6, 7, 8] and lead to a critical system inefficiency [9]. Here, we propose
a blockchain-based approach to enhance scientific reproducibility, with a focus
on life science studies and precision medicine. While the interest of encoding
permanently into an immutable ledger all the study key information–including
endpoints, data and metadata, protocols, analytical methods and all findings–has
been already highlighted, here we apply the blockchain approach to solve the issue
of rewarding time and expertise of scientists that commit to verify reproducibility.
Our mechanism builds a trustless ecosystem of researchers, funding bodies and
publishers cooperating to guarantee digital and permanent access to information
and reproducible results. As a natural byproduct, a procedure to quantify scien-
tists’ and institutions’ reputation for ranking purposes is obtained.
1 Introduction
Reproducibility is a key property of scientific endeavour [10], enabling the progressive structuring
of knowledge into innovation through a process of knowledge integration and reuse in downstream
studies. The continuous sharing of assets such as information, data and tools implies incentives,
trust and accountability within an ecosystem of networks. In life science we can count at least three
different networks, each mostly formed by competing actors: academic research, pharmaceutical
industry and funding bodies. Pharma companies systematically attempt to replicate academic studies
with a potential for clinical application: however, the total prevalence of irreproducible preclinical
studies exceeds 50%, each replication requiring between US$500,000 to US$2,000,000 investment
[11]. For 2012, a prevalence of irreproducible preclinical research was estimated to exceed 50%,
resulting in approximately US$28B/year spent in the United States alone according to [12]. Thus,
a low rate of reproducibility within life science research not only limits knowledge integration and
reuse, but it also ramps up costs of developing therapeutic drugs and it delays benefit to patients.
In order to accelerate the discovery of life-saving therapies, the key to a solid improvement in re-
producibility rate is to identify the critical leverage points inducing a change in the ecosystem; [13]
advocated that investigators and their institutions should receive specific financial incentives to di-
minish the data irreproducibility problem at the academia-industry interface, but these should be
matched by a form of money-back guarantee. However, [14] argued that reproducing findings is not
a simple story and it requires time and experience; further, even clinical studies cannot be trusted as
immune of irreproducibility in terms of clinical efficacy and risk. Both in academia and life science
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industry, the first obstacle to remove is the lack of verified compliance to a fully transparent access
to research findings, data and protocols, including the capability of tracking of all decisions and
changes along the whole course of experiments. This is a lesson that machine learning scientists
as well as genomics experts have already learnt the hard way. Developing predictive models from
massive genomics data carries a pervasive risk of selection bias [15, 16] and it requires a careful
evaluation of all causes of variability from bioinformatics procedures to biomarker identification
[17], and overall a deep commitment to provide access to data, metadata and protocols. [18] found
that almost 90% of microarray studies from a leading genetics journal was found not fully repeat-
able, mostly due to incomplete availability of data and methods. Even in the case of full availability
of data, software and methods, it has been recently pointed out that peer review and editor evaluation
provide just a filter to poor data analysis that, in more complex studies, needs preventive measures
such as education to data science and evidence-based data analysis [19].
The blockchain is a decentralized and distributed technology [20] developed to avoid the neces-
sity of authorities that regulate the exchange of money and any type of assets [21], from music to
health care. The blockchain relies on strong cryptographic protocols which are able to guarantee
the secure, (pseudo-)anonymous and trustless interactions among peers of the underlying network.
The transaction, e.g. a money transfer, is independently verified by several miners – nodes of this
system with high computational power which own a copy of the distributed ledger of any previous
transaction – who solve complex mathematical puzzles and have to reach consensus about its valid-
ity. If consensus is achieved, the transaction is accepted and encoded into a block of data which is
permanently stored in the blockchain.
The blockchain technology can be key to address the issues of replicability, accountability and trust
in scientific studies, providing an immutable ledger for all the steps, from protocols to all out-
comes. One first implementation was sketched in [22], as a blockchain-based solution to notarize
univocally the endpoint and the analytical strategies into the permanent, timestamped Bitcoin public
ledger. Since then, the enthusiasm for blockchain-based solutions has raised so high to be con-
sidered indispensable to the future of precision medicine ecosystem, improving data security, data
sharing, interoperability, patient engagement by wearable sensors, AI-based diagnostics and much
more [23].
As discussed, all members of the scientific ecosystem—from researchers to funding bodies and
publishers—are interested in fostering reproducibility to save time and investments that would oth-
erwise fund bad practices and misleading outcomes. However, the current system does not reward
appropriately those members of the community who invest in conducting rigorous and reproducible
research [4]. Here we fill this gap by proposing a blockchain-based mechanism to ignite the interest
in reproducing scientific analyses by rewarding time and expertise of researchers and institutions
that commit to verify reproducibility. Our mechanism is trustless, transparent, resilient to scientific
fraud and traceable, providing as a byproduct a natural procedure to rank authors and institutions for
their contribution to advancing science with reproducible results.
The current science ecosystem – including interdependent networks of researchers, institutions and
funding bodies – is more disintegrated than ever by competition for limited resources, with key
players in a constant rush for publishing faster than others in the best journals and trying to cen-
tralize the destination of available funding. Our mechanism, that we name PROBO network in the
following, aims at restoring cooperation among the main players of this ecosystem, by providing a
natural framework to achieve those ideals of transparency, reproducibility and credibility that should
characterize science and scientific knowledge.
2 A reproducibility mechanism: the PROBO blockchain
To cope with the issue of data analysis reproducibility, first we assemble PROBO as a sustainable
blockchain ecosystem: this requires defining the blockchain ledger where the results of an elemen-
tary transaction (a study to verify) will be notarized and a set of rules for rewarding consistently
with coins (tokens) the mining agents entitled to verification. We aim to adapt known blockchain
concepts to incentive peers’ evaluation, thus we focus more on the critical mechanisms rather than
on implementing a set of encoding hacks. The first aim is to create a self-supporting network includ-
ing all actors. The nodes of the PROBO network build an ecosystem of well established researchers,
research institutions and funding bodies, identified by a unique and persistent digital identifier such
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Figure 1: Illustration of the PROBO network. A researcher/lab (the proponent) aims to publish
her last study in the public ledger. Access to the collection of data, software and methods is pro-
vided as input, while the results are encrypted and safely encoded by a hash function. The proponent
deposits a pre-determined amount of probos coins to start a smart-contract-like mechanism which
broadcasts her request to the PROBO network, where other researchers/labs (the verifiers) will eval-
uate the quality of the study and verify its reproducibility. If enough verifiers agree on the study
reproducibility, a block encoding all relevant information is generated and added to the existing
PROBO blockchain. The system generates new probos to reward the verifiers’ efforts, as well as
to refund their expenses, and transfers back the deposit to the proponent—thus finalizing the smart
contract—who collects one more block for her scientific curriculum. See the text for the case of
rejected requests, and other details.
as the ORCID. Different approaches can be adopted to ignite the system, from sharing a predeter-
mined amount of tokens like by an initial coin offering (ICO) to equally distributing a fixed amount
of digital currency. A technical description of this phase is beyond the scope of the present work
and requires iterative interactions among all parties of the ecosystem to reach an agreement.
The proposed mechanism is summarized and illustrated in Fig. 1. One or more nodes of the network
produce a scientific work based on a data analysis, which is required to be reproduced by indepen-
dent peers. Note that we use the word reproducibility in its broader meaning, including obtaining
results that are not duplicating the original study but they are consistent with them, i.e. replicabil-
ity. To this aim, the proponent prepares the inputs as a time-stamped collection of data, software
and methods used for the analysis, providing direct and persistent access to this immutable resource
(e.g., by using existing services such as Github, Bitbucket or FigShare). In parallel, the proponent
prepares a standardized collection of outputs—encoding by tables the results of the data analysis—
-and computes an hash by means of complex cryptographic algorithms, to generate a long string of
characters which uniquely identifies the outputs. The proponent also sets the expected acceptable
reproducibility boundaries of their study by providing a set of statistical indicators in a standardized
format, including false positives rate (Type I error) and false negatives rate (Type II error), as well
as true positives and negatives rates to allow for the comparison of outputs while accounting for
variation across laboratories, systematic biases and error propagation. Recent studies have shown
that this goal can be achieved by appropriately distributing tasks with proper standardization and
cross-check procedures [24]. The proponent shall specify the expected amount of time required to
replicate the study, within a time horizon set by the network.
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Finally, the proponent creates a block request, including the inputs and the hash of the outputs,
which is broadcasted to the PROBO network. It is worth remarking that such an action might also
encode a publication request to a publisher, provided that the publisher is part of this ecosystem.
To prevent nodes from flooding the system with research that is not reproducible or that is not
worth reproducing, a smart-contract-like mechanism is introduced [21]. In fact, a certain amount
of probos —the digital currency of the system, which can be used to fund further research, buy
equipment, and so on—is asked to be deposited from the proponent for allowing their request to
be broadcasted to the network. It is worth accounting for scenarios when one proponent requires a
pipeline or a set of complementary experiments to be written in the blockchain. In that case, it is
expected to broadcast each experiment separately to facilitate the reproducibility of each phase of
the overall experiment.
The final request is transformed into a pending transaction that is freely accessible from any other
node of the network different from the proponent. Nodes, that we might indicate as verifiers, decide
which pending request is worth accepting, according to their assessment of the quality of the re-
search and their skills (e.g., it is very unlikely that a node working mainly in translational medicine
will attempt to reproduce a study from quantitative psychology). Each verifier uses the same data,
(version of) software and methods of the proponent to produce an hash of the standardized outputs.
Finally, the verifier compares her hash with the one of the proponent and if they match (mismatch),
the verifier accepts (rejects) the transaction.
A minimum number of verifiers is required in order to definitively accept or reject the proponent
request. In case of acceptance, the system generates a block of information including the inputs, the
outputs, the hash of the outputs, the identity of proponent and verifiers, as well as the time-stamp of
each activity. The block is therefore added to the blockchain, the system sends back the deposited
probos to the proponent and it generates a predefined number of probos to reward the efforts and
the expenses of the verifiers. Conversely, in case of rejection, the system does not generate new
probos and it rewards the verifiers by transferring the probos deposited by the proponent. As for the
case of acceptance, the rejection details are encoded into a block which is added to the blockchain,
to keep trace of the proponent’s attempt.
The PROBO ecosystem should also be effective in uncovering scientific misconduct in its early
stage, thus nipping in the bud unwanted horror stories running through several years (e.g. see [25]),
and made possible by an outrageous lack of reproducibility throughout all the steps of the research.
3 Discussion
The blockchain-based approach that we envision is expected to mitigate some of the issues which
are currently affecting the reproducibility of scientific analyses by widening the incentive offer. Its
sustainability will depend on both technical and social mechanisms that need to be acknowledged
and embedded in the design of the PROBO network. Here we sketch a list of relevant aspects,
knowing that additional elements may need to be detailed.
The total supply of probos in the PROBO network will depend on multiple factors, as for other exist-
ing blockchains. For instance, the total supply of bitcoins is limited to 21 million by the integer stor-
age type of the transaction output, which can be easily extended in new-generation blockchains like
the one proposed here. The total supply will be mostly affected by the parameters regulating veri-
fiers’ recompense – like the ratio between proponent’s deposit and block reward – in the case of study
acceptance, which will be determined in order to optimize the efficiency of the PROBO network and
the benefits of its nodes.
Besides the stimulus triggered by the PROBO network on activities dedicated to verify reproducibil-
ity, an interesting byproduct is that this blockchain allows a quantitative evaluation of scientists’ and
institutions’ prestige. In fact, the number of blocks written in the blockchain by proponents and
verifiers can be used to build the reputation of researchers – and, at a coarser level, of institutions –
which in turn provides a direct proxy for the quality of their research and, overall, the reproducibil-
ity of their analyses. Failures, i.e. transaction requests that have not been accepted by the network
for lack of reproducibility, are also accounted for, pushing researchers and institutions to be more
careful with the analyses they intend to add in the blockchain.
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Therefore, the proposed blockchain-like mechanism embeds a direct, transparent, objective and
unbiased way for funding bodies to rank scientists and institutions. This reputation score is expected
to be a valid alternative to Hirsch index [26] and other bibliometrics measures widely adopted for
ranking with respect to a variety of criteria, from performance to interdisciplinarity [27, 28, 29, 30,
31, 32, 33].
Additionally, ranking by the reputation score can be accounted for by decision makers to hire or fund
researchers in a trustless ecosystem; indeed the quality of scientific content and its reproducibility
should drive decisions without relying – only – on bibliometrics data, which can be mesleading or
distorted, or even fake [34, 35, 36]. Further, the same ranking score can be adopted by journals
as an additional dimension of their own prestige in terms of reproducibility and good scientific
practice, based on the papers either published or rejected, whose studies were submitted to the
PROBO blockchain.
This architecture may attract big research institutions or labs to investing into “reproducibility units”,
new groups of researchers working as verifiers in the PROBO network to produce a steady income
in terms of probos to fund further research. Indeed a first attempt to improve the quality of biomed-
ical literature as the Reproducibility Initiative, fostering independent corroboration of published
results [37], was initially supported by scientist, publishers, and private foundations and it is now
being implemented through a online marketplace for scientific experiments. Of course there is a
risk that without an embedded feedback mechanism towards authors or institutions’ reputation, the
birth of scientific facilities specialized in testing reproducibility for third parties will have no effect
or even ironically sustain the current crisis.
It is worth remarking that, as a community-based effort, the laboratories’ commitment to our
blockchain mechanism relies on the same philosophy that inspired the quest for standards and open
access to material and methods in computational biology (and -omics studies in particular) through-
out the last twenty years. Starting with the MIAME standard for microarray experiments proposed
by the FGED Society [38], a number of similar protocols for the omics types has led first to a
rationalisation attempt [39] and then to the comprehensive FAIR initiative [40] where “a diverse
set of stakeholders—representing academia, industry, funding agencies, and scholarly publishers—
have come together to design and jointly endorse a concise and measurable set of principles that we
refer to as the FAIR Data Principles”. The FAIR (Findability, Accessibility, Interoperability, and
Reusability) guidelines are aimed at maximizing the added-value attached to formal scholarly dig-
ital publishing in the broader sense, thus including data, algorithms, tools, and workflows in order
to warrant transparency, reproducibility, and reusability. All these requirements would facilitate the
procedural description of an analysis to replicate (see example in Box 1).
In summary, the blockchain-based network like the one we design in this paper has naturally built in
a rich set of options for explicit and implicit feedback mechanisms based on standardized description
of data, methods and outcomes. We argue that the ecosystem spanned by the PROBO network may
intercept a wider set of incentives than existing practice aiming to obtain a pervasive adoption of
open science and reproducibility concepts.
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